Levena Biopharma Revenue
Pharmaceutical Manufacturing • 
San Diego, California, United States • 11-20 Employees
Levena Biopharma revenue & valuation
| Annual revenue | $7,500,000 |
| Revenue per employee | $682,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $24,000,000 |
| Total funding | No funding |
Key Contact at Levena Biopharma
Alisher Khasanov
Associate Director
Company overview
| Headquarters | 4955 Directors Place, Suite 300, San Diego, CA 92121, US |
| Phone number | +18582034200 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Contract Research Organization, Antibody Drug Conjugation, Cgmp Production, Conjugation And Analytical Services, Linkers & Toxins |
| Founded | 2013 |
| Employees | 11-20 |
| Socials |
Levena Biopharma Email Formats
Levena Biopharma uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@levenabiopharma.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@levenabiopharma.com | 50% |
{first name}{last name} | johndoe@levenabiopharma.com | 50% |
About Levena Biopharma
Levena Biopharma is a global ADC CRO/CDMO dedicated to advancing Antibody Drug Conjugate programs from discovery to the clinic and beyond. In 2013, Sorrento acquired Concortis Biosystems, establishing Levena as an independent, wholly-owned subsidiary of Sorrento Therapeutics to offer the scientific community access to our leading-edge linkers, payloads, and site-specific conjugation technologies. Our mission is to collaboratively develop conjugates that maximize the therapeutic potential of our clients' native or engineered antigen-targeting biomolecular carriers (antibodies, proteins and nucleic acids) and advance precision medicine options for patients with unmet clinical needs. We welcome discussing your projects and our capabilities at our world-class facilities in: -- San Diego (R&D Headquarters, 2013) -- Suzhou (CMC and cGMP, 2017) Levena provides small and large scale proof-of-concept (POC) conjugation services as well as complete ADC characterization using advanced analytical tools such as HPLC (HIC, SEC, RP), iCIEF and LC-MS, quality assessment (Drug-to-Antibody Ratio, purity via SDS-PAGE, aggregation, endotoxin, residual drug) and in vitro pharmacology for cytotoxicity studies. Expanding on IP from Concortis starting in 2008, we continue to maintain and grow our comprehensive, in-house portfolio of leading-edge ADC solutions, enabling Levena's world-class chemistry & conjugation teams to efficiently deliver constructs with unsurpassed quality and therapeutic potential. Our proprietary and non-proprietary ADC solutions include Linkers, Payloads, L-P chemistries and site-specific conjugation platforms [C-Lock™, K-Lock™ and C-Lock™/K-Lock™ for dual-drug delivery], enabling efficient development of mechanistically-defined ADCs with exacting, reproducible performance for safety, efficacy and clinical success.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Levena Biopharma has 3 employees across 3 departments.
Departments
Number of employees
Funding Data
Levena Biopharma has never raised funding before.
Levena Biopharma Tech Stack
Discover the technologies and tools that power Levena Biopharma's digital infrastructure, from frameworks to analytics platforms.
Font scripts
JavaScript libraries
JavaScript libraries
Security
Ecommerce
Tag managers
Hosting
Security
Miscellaneous
JavaScript libraries
Analytics
JavaScript libraries
United Kingdom
Indonesia
Italy
Netherlands
Frequently asked questions
4.8
40,000 users
